摘要
目的:评价参麦注射液与注射用丹参多酚酸盐辅助治疗冠心病心衰的成本与效果。方法:采用前瞻性随机对照临床研究方法,将103例冠心病心衰患者按随机数字表法分为两组:A组55例,在常规治疗方案基础上加用参麦注射液50 ml加入5%葡萄糖溶液250 ml中静脉滴注,每天1次;B组48例,在常规治疗方案基础上加用注射用丹参多酚酸盐200 mg加入5%葡萄糖溶液250 ml中静脉滴注,每天1次。疗程均为2周。观察治疗前后两组患者临床指标改善情况及药品不良反应,并运用药物经济学方法对两种治疗方案进行评价分析。结果:A、B两组的总有效率分别为89.09%、72.92%,差异有统计学意义(P<0.05);A、B两组的不良反应发生率分别为9.09%、12.50%,差异无统计学意义(P>0.05)。两组患者的成本-效果比A组明显低于B组,差异有统计学意义(P<0.05),敏感度分析结果与其一致,说明应用参麦注射液方案的治疗成本较低。结论:选用参麦注射液辅助治疗冠心病心衰的治疗方案更经济。
OBJECTIVE：To evaluate the cost and effectiveness of Shenmai injection and Salvianolate for injection in adjuvant treatment of coronary heart disease with heart failure. METHODS：In prospective randomized controlled clinical study,103 patients with coronary heart disease with heart failure were randomized into 2 groups：55 patients in group A received Shenmai injection 50 ml added into 5% Glucose solution 250 ml intravenously on the basis of routine treatment,once a day;48 patients in group B received Salvianolate for injection 200 mg added into 5% Glucose solution 250 ml intravenously on the basis of routine treatment,once a day;treatment course lasted for 2 weeks. The improvement of clinical indicators and ADR were observed before and after treatment;2 drug treatment programs were evaluated and analyzed with pharmacoeconomics. RESULTS：Total effective rates of group A and B were 89.09% and 72.92%,with statistical significance（P0.05）;the incidence of ADR in group A and B were 9.09% and 12.50%,there was no statistical significance（P0.05）. The cost-effectiveness ratio of group A was significantly lower than that of group B,with statistical significance（P0.05）;the results of sensitivity analysis was consistent with it,indicating the cost of Shenmai injection was in low level. CONCLUSIONS：Shenmai injection is more economic in adjuvant treatment of coronary heart disease with heart failure.
出处
《中国药房》
CAS
北大核心
2015年第26期3614-3616,共3页
China Pharmacy
基金
浙江省医学会临床科研基金项目(No.2011ZYC-A105)
关键词
冠心病
心衰
参麦注射液
注射用丹参多酚酸盐
成本-效果分析
Coronary heart disease
Heart failure
Shenmai injection
Salvianolate for injection
Cost-effectiveness analysis
